PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 11, 2026Cancer

Circulating tumor DNA in early breast cancer: Evidence, challenges, next steps

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSerena Di CosimoVAValentina AppiertoCRCarolina Reduzzi

Discussion

Loading...

Member takes

Overview

Narrative review examines prognostic value and challenges of ctDNA in early breast cancer, suggesting implications for clinical practice.

Key Points

  • This review aims to evaluate the role of circulating tumor DNA (ctDNA) in early breast cancer, addressing challenges and future directions.
  • Narrative review of current literature on ctDNA in early breast cancer.
  • Discussion on methodological standardization and clinical applicability.
  • Examination of evidence for ctDNA in response monitoring and disease detection.
  • ctDNA shows potential for identifying minimal residual disease earlier than traditional methods.
  • Challenges in routine clinical adoption include low tumor DNA shedding and assay performance variability.
  • Emerging strategies for ctDNA-guided therapies and monitoring were highlighted, indicating future relevance.

Cite This Study

Cosimo et al. (2026) studied this question.

synapsesocial.com/papers/6a51e019c18d7f28ca500b40https://doi.org/10.1002/cncr.70521
View Full Paper
Ask AI
Bookmark
Share